The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
Official Title: Clinical Validation of the ColonoSight Test: a Multi-target Stool RNA (Mt-sRNA) Assay for Colorectal Neoplasia Screening in Average-risk Individuals Aged >45 Years Old
Study ID: NCT04739722
Brief Summary: This study will be a prospective analysis conducted by Geneoscopy Inc. to evaluate the Colosense test, which is a multi-target stool RNA test for colorectal screening.
Detailed Description: Patients who are eligible for a colonoscopy (i.e., average risk individuals 45 years of age and older who are not up-to-date with screening guidelines) will be enrolled in the study. Stool samples returned to Geneoscopy's Laboratories by the participant will be subjected to the Colosense test system, and a result will be generated. The result will be compared to an optical colonoscopy to determine: 1) sensitivity for colorectal cancer, advanced adenomas, and other precancerous adenomas and 2) specificity for hyperplastic polyps and no findings on a colonoscopy. This study will be used for the clinical validation of the Colosense test.
Minimum Age: 45 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Geneoscopy, Inc., Saint Louis, Missouri, United States
Elligo Health Research, Austin, Texas, United States
Name: Elizabeth Wurtzler, PhD
Affiliation: Geneoscopy, Inc.
Role: STUDY_CHAIR
Name: Faith Holmes, MD
Affiliation: Elligo Health Research
Role: PRINCIPAL_INVESTIGATOR